The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1
SKYRIZI met its primary endpoint (ACR20 at Week 24) in 2 clinical trials.1
ACR20/50/70, complete resolution of enthesitis/dactylitis, and minimal disease activity at Week 24 with results up to ~1 year in PsA.1-3 *
PASI 90 response vs placebo at Week 24 with response rates at 1 year in PsA.2,3 *
Evaluated in 19 clinical trials (2 PsA, 17 Ps). The safety profile in PsA is generally consistent with the safety profile of Ps.1,4
>95% preferred† commercial and Medicare Part D coverage for PsA5‡
*In an OLE, there is a potential for enrichment of the long-term data in remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
†Preferred means SKYRIZI is placed on the plan's preferred formulary.
ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR50=improvement of at least 50% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR70=improvement of at least 70% in tender joint count, swollen joint count, and at least 3 other core criteria. PASI 90=≥90% improvement in Psoriasis Area and Severity Index.
National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of July 2022.
‡Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
§Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
Peer-Led Discussions about skyrizi FOR patients with PsA
EFFICACY & SAFETY RESULTS WITH SKYRIZI
Dr. Schwartzman and Dr. Khattri review the clinical efficacy endpoints from the PsA trials, including ACR20/50/70, ACR components such as patient-reported pain, and enthesitis and dactylitis, then conclude with a discussion of SKYRIZI's safety profile across 2 indications.
‖As of 10/2021. New patients defined as bio-naïve; switch patients defined as bio-experienced switching biologics. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP) through proprietary method on diagnosis classification.
ACR20 Achieved At Week 24 with Response Rates Sustained At 1 year1-3,7,8
57% of patients achieved ACR20 at Week 24 vs 34% for placebo (primary endpoint)¶
70% observed ACR20 at Week 52 in OLE (after 5 doses)
51% of patients achieved ACR20 at Week 24 vs 27% for placebo (primary endpoint)¶
59% observed ACR20 at Week 52 in OLE (after 5 doses)
¶Multiplicity-controlled P≤0.001 SKYRIZI vs placebo comparison.
In an OLE, there is a potential for enrichment of the long-term data in remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
KEEPsAKE 1 (N=964) and KEEPsAKE 2 (N=443) were 2 randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI 150 mg vs placebo over 24 weeks with a long-term, open-label extension for up to an additional 204 weeks. Both studies enrolled adult patients with active psoriatic arthritis. In KEEPsAKE 1, the study population had an inadequate response or intolerance to at least 1 csDMARD while in KEEPsAKE 2 patients had an inadequate response or intolerance to at least 1 biologic therapy OR to at least 1 csDMARD.1-3